Diffuse Large B-Cell Lymphoma
Conditions
Interventions
test group:Conventional chemotherapy and jianpiyishen granules
Sponsors
Guang'anmen Hospital
Eligibility
Sex/Gender
All
Age
60 Years to 110 Years
Inclusion criteria
Inclusion criteria: 1. Patients with CD20-positive initial treatment of large B-cell lymphoma with pathological diagnosis; 2. Age = 60 years old, male or female; 3. Ann Arbor/Cotswords Phase I-IV; 4. CGA assessment of patients before treatment, and elderly vulnerable patients who are not suitable for standardized therapy must meet one of the following criteria: 1) ADL in the MCIRS-G score; 4) Patients with an age = 80 years old need to meet: ADL =5, or IADL =7, or 0-1 in the MCIRS-G score of grade 3 to 4 (or > 5 grade 2 complications); 5. The expected survival period is more than 6 months; 6. Alanine aminotransferase (AST)= 2.5×ULN, alanine aminotransferase (ALT)=2.5×ULN, serum creatinine Cr=1.5×ULN; 7. Volunteer to participate in this study and sign an informed consent form.
Exclusion criteria
Exclusion criteria: 1. Those who have a previous history of blood or non-hematologic tumors undergoing chemoradiotherapy; 2. In the past 5 years, there is a history of malignant tumors other than skin squamous cell carcinoma, skin basal cell carcinoma, and cervical carcinoma in situ; 3. Patients with central nervous system involvement; 4. There is a serious infection that is not controlled; 5. Have other uncontrolled diseases and the researcher believes that it is not suitable for joiners; 6. Participating in other clinical studies; 7. Persons infected with COVID-19(excluding cured patients); 8. Patients with poor adherence.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ORR; | — |
Secondary
| Measure | Time frame |
|---|---|
| mPFS;EORTC QLQ-C30 scale;mOS;IADL scale; | — |
Countries
China
Contacts
Public ContactWujie
Outcome results
None listed